Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 21;25(20):11299.
doi: 10.3390/ijms252011299.

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients

Vincenzo Quagliariello  1 , Maria Laura Canale  2 , Irma Bisceglia  3 , Martina Iovine  1 , Vienna Giordano  1 , Ilaria Giacobbe  1 , Marino Scherillo  4 , Domenico Gabrielli  5 , Carlo Maurea  6 , Matteo Barbato  1 , Alessandro Inno  7 , Massimiliano Berretta  8 , Andrea Tedeschi  9 , Stefano Oliva  10 , Alessandra Greco  11 , Nicola Maurea  1
Affiliations
Review

Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients

Vincenzo Quagliariello et al. Int J Mol Sci. .

Abstract

Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated several beneficial cardiovascular effects, including atherosclerosis and heart failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits and systemic anti-inflammatory effects in patients with type-2 diabetes through the activation of cAMP and PI3K/AkT pathways and the inhibition of NLRP-3 and MyD88. In this narrative review, we highlight the biochemical properties of GLP-1 RA through a deep analysis of the clinical and preclinical evidence of the primary prevention of cardiomyopathies. The overall picture of this review encourages the study of GLP-1 RA in cancer patients with type-2 diabetes, as a potential primary prevention strategy against heart failure and atherosclerosis.

Keywords: GLP-1 receptor; cancer; cardio-oncology; cardioprotection; inflammation; metabolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Overall picture of anti-antherosclerotic and cardioprotective properties of GLP-1 RA in cardio-oncology.
Figure 2
Figure 2
Cardioprotective mechanisms of GLP1-RA against anticancer treatment–induced cardiotoxicity.
See this image and copyright information in PMC

References

    1. Brunton S.A., Wysham C.H. GLP-1 receptor agonists in the treatment of type 2 diabetes: Role and clinical experience to date. Postgrad. Med. 2020;132:3–14. doi: 10.1080/00325481.2020.1798099. - DOI - PubMed
    1. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Mol. Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102. - DOI - PMC - PubMed
    1. Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740–756. doi: 10.1016/j.cmet.2018.03.001. - DOI - PubMed
    1. Guyton J., Jeon M., Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am. J. Health Syst. Pharm. 2019;76:1739–1748. doi: 10.1093/ajhp/zxz179. - DOI - PubMed
    1. Cheng D., Yang S., Zhao X., Wang G. The Role of Glucagon-Like Peptide-1 Receptor Agonists [GLP-1 RA] in Diabetes-Related Neurodegenerative Diseases. Drug Des. Devel Ther. 2022;16:665–684. doi: 10.2147/DDDT.S348055. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources